昆藥集團(600422.SH):擬轉讓昆明銀諾51%股權
格隆匯 9 月 29日丨昆藥集團(600422.SH)公佈,公司擬將持有的昆明銀諾醫藥技術有限公司(“昆明銀諾”或“標的公司”)51%股權,按照標的公司整體估值人民幣3.26億元,以合計人民幣16626萬元或等值美元的股權轉讓對價轉讓給景得(廣州)股權投資合夥企業(有限合夥)等九家公司。
公司經過多年深耕和發展,已在心腦血管、骨科、免疫、抗腫瘤等治療領域形成一定的研發優勢和產品梯度。未來,公司將重點佈局心腦血管、骨科、自身免疫、抗腫瘤等核心治療領域,並通過持續動態評估研發進度及研發優勢,不斷優化和完善創新研發產品管線。
此次交易,有利於公司將重心聚焦於核心治療領域,將資源和精力投入核心產品管線的研發,加速推動公司實現創新型國際化藥企的戰略轉型。同時,此次交易將使公司獲得較好的收益回報,進一步優化公司現金流,有利於公司持續穩健發展,符合公司及全體股東利益。此次交易完成後,公司將不再持有標的公司股權。
此次股權轉讓完成後,預計該投資事項將產生收益約人民幣8313萬元,具體以會計師年度審計確認後結果為準
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.